Hyperkalemia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented by Drug, Type of Disease (Acute Hyperkalemia and Chronic Hyperkalemia), and Geography

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

16.79 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The increasing prevalence rates of acute hyperkalemia and chronic hyperkalemia are due to the upsurge in the number of geriatric population, globally. The aging population and advances in medical technology are likely to contribute to the increasing prevalence of heart failure and chronic kidney diseases, and consequently, a larger pool of patients is likely to be at risk for hyperkalemia. According to the data from the World Population Prospects: The 2017 Revision, the number of older people, those aged 60 years or above, is expected to be more than double by 2050 and more than triple by 2100, rising from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion in 2100. 

Hyperkalemia has been reported in around 5% of the general population, worldwide. According to the National Kidney Foundation, in heart failure patients with chronic kidney disease (CKD), the prevalence of hyperkalemia can be up to 20%, and it is associated with an increased risk of mortality and major adverse cardiovascular events. According to the United States Renal Data System (USRDS) (2018), the overall prevalence of CKD (Stages 1-5) among the adult general population in the United States was 14.8% during 2013-2016.

Potassium is regarded as one of the most effective alkalinizing agents for the treatment of hyperkalemia. Moreover, its use in the management of acute and chronic hyperkalemia, related to advanced medical illness, is considered as the standard care in most parts of the world.

Thus, increase in the number of patients undergoing treatment of hyperkalemia is likely to drive the growth of the market.

Scope of the Report

Hyperkalemia, a condition of elevated serum potassium, arises from disturbances to potassium homeostasis within the body.​ The hyperkalemia treatment market has been sub-segmented based on drugs, type of disease, and geography.

By Drug
Sodium Zirconium Cyclosilicate
Beta2 Agonist
Sodium Polystyrene Sulfonate
Other Drugs
By Type of Disease
Acute Hyperkalemia
Chronic Hyperkalemia
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chronic Hyperkalemia dominates the Global Hyperkalemia Treatment Market

Chronic hyperkalemia from impaired renal excretion may involve one or more of the conditions, such as decreased mineralocorticoid activity, decreased distal Na+ delivery, and CCD dysfunction. Considered individually, these pathophysiologic processes generally do not create chronic hyperkalemia, but together their effects become clinically significant.​ Chronic hyperkalemia is one of the most prevalent disease conditions among patients suffering from CKDs. As per the National Kidney Foundation, more than 37 million people in the United States have CKDs, and over 80% of them do not know they have it. ​Moreover, the management of chronic hyperkalemia requires confirmation, increased laboratory surveillance, dietary review and counseling, a review of medications (prescribed, over-the-counter, and herbal), and, if needed, a potassium-lowering medication and/or a diuretic.​ As the kidney function declines, the prevalence in patients with CKDs increases; it ranges from 5% to 50% in the patients.​Overall, the chronic hyperkalemia segment of the market studied is expected to grow over the forecast period. This is expected to be fueled by the increasing prevalence of chronic hyperkalemia, with an upsurge in geriatric population levels and related ailments.​

To understand key trends, Download Sample Report

North America Dominates the Global Hyperkalemia Treatment Market

The presence of leading market players, the high prevalence of disease-related conditions, favorable healthcare policies, and high disposable income of the patients bolster demand for advanced therapeutic options, thereby, are expected to contribute to the dominance of the United States, throughout the forecast period.​ Moreover, the growing incidence of hyperkalemia and the rising number of geriatric population are some major factors aiding the growth of the market. Thus, the huge patient population is anticipated to increase the number of patients who opt for treatment, which, in turn, is expected to support growth in the near future.​ For instance, in the United States, the federal government has been running various awareness campaigns through various initiatives, which is expected to have a positive impact on the market studied. ​Hence, this increasing adoption of a patient-centric approach by healthcare payers is expected to drive the US hyperkalemia treatment market, during the forecast period.​

To understand geography trends, Download Sample Report.

Competitive Landscape

The hyperkalemia market is consolidated, dominated by a few players. The hyperkalemia market underwent extensive changes with the introduction of Veltassa at the beginning of 2016 which represented the first new therapy for the treatment of hyperkalemia in over 50 years. Few key market players in the market are AstraZeneca Plc, Ardelyx, Vifor Pharma Management Ltd, Sanofi S.A. and Perrigo Company plc.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Hyperkalemia

      2. 4.2.2 Rising Focus on Research and Development and Increasing Number of Strategic Alliances

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Sodium Zirconium Cyclosilicate

      2. 5.1.2 Beta2 Agonist

      3. 5.1.3 Sodium Polystyrene Sulfonate

      4. 5.1.4 Other Drugs

    2. 5.2 By Type of Disease

      1. 5.2.1 Acute Hyperkalemia

      2. 5.2.2 Chronic Hyperkalemia

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Ardelyx

      3. 6.1.3 Perrigo Company Plc

      4. 6.1.4 Vifor Pharma Management Ltd

      5. 6.1.5 Sanofi SA

      6. 6.1.6 Relypsa Inc.

      7. 6.1.7 Odan Laboratories Ltd

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports